Pharmacokinetics of Propoxyphene

Pearson, Richard M.

doi:10.1177/096032718400300104

Cited by 8 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also found 29 cases of hepatic injuries in patients treated with dextropropoxyphene in international publications. It was suggested that the active dextropropoxyphene metabolite, norpropoxyphene, could induce these hepatic ADRs via an immunoallergic mechanism [19, 20].…”

Section: Discussionmentioning

confidence: 99%

Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol)

Tavassoli

Lapeyre‐Mestre

Sommet

et al. 2009

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Three ‘weak’ opioid analgesics are marketed in France and other European countries in association with paracetamol. • They are very largely used, but to our knowledge there is no large study comparing the reporting rate of adverse drug reactions (ADRs) between these different step 2 analgesic combinations to determine the safest one. WHAT THIS STUDY ADDS • The aim of this study was to compare reporting rate of ADRs with three step 2 combinations according to their consumption in France. • The results show that among these combinations, reporting rate and ‘seriousness’ of reported ADRs are the highest with tramadol/paracetamol (TRM+P) and the lowest with codeine/paracetamol. • The safety of TRM+P needs to be urgently investigated with more methodologically rigorous studies. AIMS Three ‘weak’ opioid analgesics in association with paracetamol are marketed in France as step 2 analgesics: dextropropoxyphene, tramadol and codeine. These combinations are involved in several adverse drug reactions (ADRs), but no data are available about their comparative reporting rate. The aim was to compare the reporting rate of ADRs between tramadol/paracetamol (TRM+P), codeine/paracetamol (COD+P) and dextropropoxyphene/paracetamol (DXP+P). METHODS All spontaneous reports submitted to the French Pharmacovigilance Database from 1 January 1987 to 31 December 2006 suspected to be induced by one of the three step 2 analgesic combinations (DXP+P, TRM+P, COD+P) were extracted. Their consumption for the same period was obtained from the French Drug Agency. The number of ADRs, serious ADRs and different organ classes of ADRs were compared according to their consumption. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each variable using DXP+P as reference. RESULTS The reporting rate of ADRs was calculated as 24.9/100 000 person‐years for DXP+P, 44.5/100 000 person‐years for TRM+P and 12.5/100 000 person‐years for COD+P. The reporting rate (OR 0.56, 95% CI 0.50, 0.63) and ‘seriousness»’ (OR 0.65, 95% CI 0.53, 0.80) of ADRs were significantly higher with TRM+P than with DXP+P. However, hepatobiliary ADRs were significantly more frequent with the DXP+P combination (OR 2.62, 95% CI 1.59, 4.37). In contrast, the reporting rate (OR 1.99, 95% CI 1.82, 2.18) and ‘seriousness’ (OR 2.64, 95% CI 2.24, 3.11) of ADRs were significantly higher with DXP+P than with COD+P. CONCLUSIONS Among the three step 2 analgesic combinations, reporting rate and ‘seriousness’ of ADRs are the highest with TRM+P and the lowest with COD+P. Our study suggests that the safety profile of DXP+P is worst than that of COD+P.

show abstract

Section: Discussionmentioning

confidence: 99%

Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol)

Tavassoli

Lapeyre‐Mestre

Sommet

et al. 2009

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Previous reports suggest dextropropoxyphene is rapidly absorbed from the gastrointestinal tract and detectable in plasma 5 min after administration of the napthylate and hydrochloride by mouth (19), the peak concentration in plasma is reached between 1 and 2 h after oral administration to an empty stomach (20). Long plasma half-lives of dextropropoxyphene and norpropoxyphene have been reported in overdose (21), following repeated doses (22) and in the elderly (23). Half-lives of 14.6 h (24), 17.9 to 30.5 (21), 35.5 (23), for dextropropoxyphene and 6.1 to 32.9 (22), 53.3 (23) for norpropoxyphene have been reported.…”

Section: Discussionmentioning

confidence: 98%